BeyondSpring Inc.
$1.78
▲
2.07%
2026-04-21 05:51:01
beyondspringpharma.com
NCM: BYSI
Explore BeyondSpring Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$73 M
Current Price
$1.78
52W High / Low
$3.44 / $1.21
Stock P/E
—
Book Value
$-0.8
Dividend Yield
—
ROCE
-72.39%
ROE
3.09%
Face Value
—
EPS
$-0.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
44
Beta
0.51
Debt / Equity
-0.01
Current Ratio
1.54
Quick Ratio
1.54
Forward P/E
-3.7
Price / Sales
—
Enterprise Value
$67.48 M
EV / EBITDA
-7.62
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
| 2. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 3. | Atossa Therapeutics, Inc. | $6.17 | — | $50.2 M | — | -94.38% | -62.74% | $19.35 / $3.76 | $4.57 |
| 4. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 5. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 6. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 7. | ORIC Pharmaceuticals, Inc. | $10.89 | — | $1.09 B | — | -36.81% | -41.27% | $14.93 / $4.52 | $3.9 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.6 M | -1.79 M | -1.95 M | -2.61 M | -1.7 M | — |
| Net Profit | -2.14 M | -1.54 M | -1.81 M | 4.48 M | -1.73 M | — |
| EPS in Rs | -0.05 | -0.04 | -0.04 | 0.11 | -0.04 | -0.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 1.35 M |
| Operating Profit | -8.95 M | -8.75 M | -15.08 M | -37.24 M |
| Net Profit | -1.01 M | -11.12 M | -21.03 M | -33.28 M |
| EPS in Rs | -0.02 | -0.27 | -0.51 | -0.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 25.93 M | 34.31 M | 24.81 M | 46.22 M |
| Total Liabilities | 49.92 M | 48.6 M | 48.27 M | 49.23 M |
| Equity | -32.16 M | -32.9 M | -26.8 M | -5.98 M |
| Current Assets | 20.88 M | 28.58 M | 18.42 M | 38.52 M |
| Current Liabilities | 13.58 M | 11.01 M | 7.96 M | 7.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.77 M | -16.44 M | -16.47 M | -28.15 M |
| Investing CF | 10.79 M | -12.01 M | -0.1 M | 18.25 M |
| Financing CF | 4.97 M | 26.79 M | 0 M | 3.43 M |
| Free CF | -19.82 M | -16.67 M | -16.57 M | -28.18 M |
| Capex | -0.05 M | -0.22 M | -0.1 M | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 47.1% | 36.82% | — | — |
| Profit Margin % | — | — | -2463.29% | — |
| Operating Margin % | — | — | -2756.4% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -2654.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.